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The prevalence of type 2 diabetes in youth is increasing, but little is known re
garding the occurrence of related complications as these youths transition to
adulthood.
METHODS

We previously conducted a multicenter clinical trial (from 2004 to 2011) to evalu
ate the effects of one of three treatments (metformin, metformin plus rosiglita
zone, or metformin plus an intensive lifestyle intervention) on the time to loss of
glycemic control in participants who had onset of type 2 diabetes in youth. After
completion of the trial, participants were transitioned to metformin with or with
out insulin and were enrolled in an observational follow-up study (performed from
2011 to 2020), which was conducted in two phases; the results of this follow-up
study are reported here. Assessments for diabetic kidney disease, hypertension,
dyslipidemia, and nerve disease were performed annually, and assessments for
retinal disease were performed twice. Complications related to diabetes identified
outside the study were confirmed and adjudicated.
RESULTS

At the end of the second phase of the follow-up study (January 2020), the mean
(±SD) age of the 500 participants who were included in the analyses was 26.4±2.8
years, and the mean time since the diagnosis of diabetes was 13.3±1.8 years. The
cumulative incidence of hypertension was 67.5%, the incidence of dyslipidemia was
51.6%, the incidence of diabetic kidney disease was 54.8%, and the incidence of
nerve disease was 32.4%. The prevalence of retinal disease, including more ad
vanced stages, was 13.7% in the period from 2010 to 2011 and 51.0% in the period
from 2017 to 2018. At least one complication occurred in 60.1% of the partici
pants, and at least two complications occurred in 28.4%. Risk factors for the de
velopment of complications included minority race or ethnic group, hyperglyce
mia, hypertension, and dyslipidemia. No adverse events were recorded during
follow-up.
CONCLUSIONS

Among participants who had onset of type 2 diabetes in youth, the risk of com
plications, including microvascular complications, increased steadily over time
and affected most participants by the time of young adulthood. Complications
were more common among participants of minority race and ethnic group and
among those with hyperglycemia, hypertension, and dyslipidemia. (Funded by the
National Institute of Diabetes and Digestive and Kidney Diseases and others;
ClinicalTrials.gov numbers, NCT01364350 and NCT02310724.)
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T

he incidence of youth-onset type 2
diabetes has increased in parallel with the
rise in the number of children with obe
sity in the United States.1,2 In the period from
2002 to 2012, the incidence of type 2 diabetes
increased by 4.8% each year.3 Pathologic pro
cesses associated with diabetes, including the
development of insulin resistance and the dete
rioration of beta-cell function, progress more
rapidly in youth-onset type 2 diabetes than in
adult-onset diabetes. These factors result in worse
glycemic control and an increased risk of early
diabetes-related complications.1,4-7
The SEARCH for Diabetes in Youth registry
study and a registry study in the Canadian prov
ince of Manitoba showed a higher prevalence of
diabetic kidney disease, hypertension, retinal dis
ease, and peripheral nerve disease among youths
with type 2 diabetes than among those with
type 1 diabetes.4,8 Both studies were cross-sec
tional; the SEARCH study reported post hoc diag
noses, and the Canadian study identified out
comes in an administrative database. In addition,
the burden of complications at 21 years of age in
the cohort in the SEARCH study was estimated
with the use of modeling. After calculation of a
standardized mortality ratio, data from the Aus
tralian National Death Index and the Australian
National Diabetes Services Scheme showed an
inverse relationship between the age at onset of
type 2 diabetes and a long-term risk of end-stage
kidney disease.1,9
The lack of prospective longitudinal data has
challenged the development of evidence-based
guidelines for prevention and management of
complications in youth-onset type 2 diabetes.
We hypothesized that longitudinal follow-up of
participants in the Treatment Options for Type 2
Diabetes in Adolescents and Youth (TODAY)
clinical trial would show a rapid accumulation
of diabetes-related complications, including the
emergence of potentially life-threatening endorgan damage. We report here the overall inci
dence and clustering of complications. Subse
quent analyses will provide a deeper exploration
of the particular risk factors, treatments, and
associations of each complication.

able with the full text of this article at NEJM
.org) have been published previously.10 In brief,
699 participants were enrolled at 15 centers
across the United States from 2004 through
2009. Participants were 10 to 17 years of age and
had a duration of type 2 diabetes (defined ac
cording to American Diabetes Association 2002
criteria10) of less than 2 years, a body-mass index
(BMI [the weight in kilograms divided by the
square of the height in meters]) at or above
the 85th percentile, a fasting C-peptide level of
more than 0.6 ng per milliliter, and a negative
test for pancreatic antibodies. Eligible partici
pants were randomly assigned to receive metfor
min monotherapy, metformin plus rosiglitazone,
or metformin plus an intensive lifestyle interven
tion. Participants were followed for an average of
3.9 years (range, 2.0 to 6.5). A total of 319 par
ticipants (45.6%) had lack of glycemic control
(the primary outcome): 51.7% of the participants
who received metformin alone, 38.6% of those
who received metformin plus rosiglitazone, and
46.6% of those who received metformin plus a
lifestyle intervention.10 Data on adverse events
that occurred during the trial were published
previously10 and are also reported in Table S1
in the Supplementary Appendix, available at
NEJM.org.
Design of the Follow-up Study

In 2011, we enrolled 572 participants (81.8%)
from the TODAY trial in the TODAY2 follow-up
study, which was conducted in two phases. In
the first phase (March 2011 through February
2014), participants received all diabetes care
from the study and were treated with metformin
with or without insulin to maintain glycemic
control; data on adverse events were collected in
the same manner as in the TODAY trial. From
March 2014 through January 2020, a total of
518 participants were transitioned to the fully
observational second phase of the study; there
were annual study visits, but medical manage
ment was provided by the participants’ health
care providers. Because the study offered no
treatment or intervention in this phase, only
adverse events related to study procedures were
evaluated. The two phases of the study pro
vided a combined average duration of follow-up
Me thods
of 10.2 years. Participants who had a positive re
Design of the Clinical Trial
sult from a genetic analysis for maturity-onset
The analysis of the primary outcome of the diabetes of the young were excluded from all
TODAY clinical trial and the protocol (also avail analyses.
n engl j med 385;5

nejm.org

July 29, 2021

417

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on March 10, 2022. For personal use only. No other uses without permission.
Copyright © 2021 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

Oversight

The study was approved by the institutional re
view board at each participating center. All partici
pants and their parents or guardians provided
written informed consent or assent as appropri
ate for the age of the participant, according to
local guidelines. The study was designed by the
TODAY Study Group, which collected and ana
lyzed the data and vouches for the accuracy of
the data and analyses. The first draft of the
manuscript was written by the manuscript writ
ing group, and the steering committee made the
decision to submit the manuscript for publica
tion. No confidentiality agreements were imposed
by the main sponsor (the National Institute of
Diabetes and Digestive and Kidney Diseases).
Definitions of Complications

Similar algorithms for the classification of dia
betes-related complications were used in the
clinical trial and in the two phases of the followup study, with differences in the frequency of
data collection incorporated in the algorithms.
All laboratory assays were performed at North
west Lipids Research Laboratory according to
methods described previously.11 A detailed descrip
tion of the analysis methods and the definitions
of complications are provided in the Detailed
Research Methods section in the Supplementary
Appendix and are described briefly below.
Hypertension

of

m e dic i n e

Albuminuria as a Marker of Diabetic Kidney
Disease

Urine samples were collected annually. If abnor
mal values were found, testing was repeated on
the first sample obtained in the morning. Mod
erate albuminuria was defined as a ratio of urine
albumin (in milligrams) to creatinine (in grams)
of 30, and severe albuminuria as a ratio of at least
300 on at least two of three determinations.14
Diabetic Nerve Disease

Scores on the Michigan Neuropathy Screening
Instrument (MNSI) and the Semmes–Weinstein
monofilament examination were performed an
nually.15 Scores on the MNSI range from 0 to 8,
with higher scores indicating more severe symp
toms of neuropathy. The MNSI examination was
considered abnormal if the score was higher than
2 on at least two consecutive assessments. The
Semmes–Weinstein monofilament examination
was considered abnormal if fewer than 8 of 10
responses were correct on at least two consecu
tive examinations.15
Diabetic Eye Disease

Fundus photography was performed twice for
research purposes (in 2010 or 2011 and in 2017
or 2018) and graded at a centralized reading
center by examiners who were unaware of the
participants’ assigned treatments.16 Eye disease
was defined as a grade of at least 20 according
to criteria in the protocol of the Early Treatment
Diabetic Retinopathy Study (grades range from
10 to 85, with higher values indicating a greater
degree of retinopathy), or clinically significant
macular edema, or both.

Blood pressure was measured at every visit. Hyper
tension was defined as a blood pressure in the
95th percentile or higher for age, sex, and height;
a systolic blood pressure of at least 130 mm Hg or
a diastolic blood pressure of at least 80 mm Hg
on three consecutive occasions; or an elevated Adjudication of Events Occurring Outside
blood pressure followed by initiation of anti the Study
hypertensive therapy.12
During semiannual follow-up, participants under
went a structured interview to identify relevant
Dyslipidemia
events that had occurred since the previous visit.
Fasting lipid profiles were obtained annually. Medical records were obtained for adjudication
Low-density lipoprotein (LDL) cholesterol dyslip by the comorbidity assessment committee ac
idemia was defined as consecutive levels of at cording to prespecified criteria from national
least 130 mg per deciliter (3.37 mmol per liter), guidelines.
calculated with the use of the Friedewald equation.
Triglyceride dyslipidemia was defined as con Statistical Analysis
secutive values of triglycerides of at least 150 mg Demographic, metabolic, and nonmetabolic
per deciliter (1.69 mmol per liter) or a single ele characteristics are presented as means and stan
vated lipid value followed by initiation of lipid- dard deviations or percentages. The percentages
lowering therapy.13
of participants in each phase of the study in
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whom glycemic control was not achieved or who
had hypertension, LDL or triglyceride dyslipid
emia, or moderate or severe albuminuria at the
end of the clinical trial are reported. Complica
tions were grouped together to obtain global
classifications: moderate and severe albumin
uria were classified as kidney disease, abnormal
MNSI examination and monofilament results as
nerve disease, and LDL or triglyceride dyslipid
emia as dyslipidemia. The percentage of partici
pants with eye disease was computed. Microvas
cular events (nerve, retinal, and kidney disease)
were aggregated to identify the first occurrence
of any event. Kaplan–Meier estimates were used
to estimate all cumulative incidences. Separate
univariable and multivariable Cox proportionalhazards regression models that included all
available data from all participants were used to
estimate the overall risk of any microvascular
complication for selected covariates. Covariates
that were prespecified on the basis of known
associations were included in the Cox models
as fixed or time-varying covariates, including
time-weighted arithmetic mean values for gly
cated hemoglobin, BMI, and insulin sensitivity
(1 ÷ fasting insulin). For participants with a
missing covariate value, the previous observed
value was carried forward. All enrolled partici
pants, irrespective of length of follow-up, were
grouped according to the number and type of
complications. The associations between the
number of microvascular complications and risk
factors were assessed with the use of a propor
tional-odds cumulative logit model. Adjudicated
complications that occurred during the study
were tallied, and the corresponding event rates
were computed. Analyses were performed with
SAS software, version 9.4 (SAS Institute). All
analyses were repeated with the use of a sensitiv
ity cohort that included participants who com
pleted an end-of-study visit for which laboratory
values were available.

R e sult s
Demographic and Metabolic Characteristics

The characteristics of the cohorts were similar
in the TODAY trial and in both phases of the
TODAY2 study (Tables 1 and S2). At the end of
the study, the mean (±SD) age of the 500 par
ticipants who were assessed from March 2014
through January 2020 and were included in the
n engl j med 385;5

analyses was 26.4±2.8 years, and the mean time
since the diagnosis of diabetes was 13.3±1.8
years. A total of 22 participants who had con
firmed maturity-onset diabetes of the young
were excluded from all the analyses.
The median glycated hemoglobin level in
creased over time, and the percentage of partici
pants with a glycated hemoglobin level in the
nondiabetes range (<6% [48 mmol per mole])
decreased from 75% at baseline (i.e., the time of
entry into the clinical trial) to 19% at 15 years
(i.e., the end of the follow-up study), and the
percentage with a glycated hemoglobin level of
at least 10% (86 mmol per mole) was 0% at base
line and 34% at 15 years (Fig. 1). The BMI in
creased from baseline (reaching a plateau at 3 to
9 years), followed by a gradual decrease; but the
overall median BMI remained in the narrow
range of 35.0 to 37.5 (Fig. S1). The diabetes
medications that were being taken by the par
ticipants at the end of the study remained al
most exclusively insulin and metformin, with
both being prescribed to nearly 50% of the par
ticipants by the time of their final visit; more
than a quarter of the participants were taking no
medication (Table S3).
Hypertension and Dyslipidemia

The prevalence of hypertension at baseline was
19.2%, and the cumulative incidence at 15 years
was 67.5% (Fig. 2). Dyslipidemia was present in
20.8% of the participants at baseline, and the
cumulative incidence at 15 years was 51.6%.
There were no differences in the incidences of
hypertension or dyslipidemia according to the
original treatment assignment.
Kidney, Nerve, and Eye Disease

The prevalence of kidney disease at baseline was
8.0%, and the cumulative incidence at 15 years
was 54.8%. At baseline, 1.0% of the participants
had nerve disease, and the cumulative incidence
at 15 years was 32.4%. Retinal disease was as
sessed twice, which prevented determination of
cumulative incidence. At the first assessment (in
2010 or 2011), 13.7% had very mild nonprolif
erative diabetic retinopathy. After an additional
7 years (in 2017 or 2018), 51.0% had eye disease,
including 8.8% with moderate to severe retinal
changes and 3.5% with macular edema (Table S4).
The cumulative incidence of any microvascu
lar complication was 50.0% by 9 years and
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Table 1. Characteristics of the Participants.*
TODAY Clinical Trial
Cohort
(N = 677)

TODAY2 Study,
Phase 1 Cohort
(N = 550)

TODAY2 Study,
Phase 2 Cohort
(N = 500)

14.0±2.0

13.9±2.0

13.8±2.0

65.0

65.1

65.4

Hispanic

39.9

39.8

38.2

Non-Hispanic Black

33.1

33.6

34.8

Non-Hispanic White

19.5

19.3

19.2

7.5

7.3

7.8

Characteristic
Baseline
Age — yr
Female sex — %
Race and ethnic group — %†

Other
Lived in household with income <$25,000 — %

41.7

42.8

44.5

Time since diagnosis of type 2 diabetes — mo

7.8±5.8

7.7±5.9

7.8±5.9

6.0±0.7

6.0±0.7

6.0±0.8

42.0±7.7

42.0±7.7

42.0±8.7

35.1±7.6

35.0±7.8

35.1±7.8

Metformin alone

33.4

33.8

33.6

Metformin plus rosiglitazone

33.5

32.9

33.0

Metformin plus lifestyle intervention

33.1

33.3

33.4

45.6

47.3

46.8

Hypertension

42.4

44.9

44.6

Low-density lipoprotein dyslipidemia

12.9

13.3

12.4

Triglyceride dyslipidemia

32.9

33.8

32.0

Moderate or severe albuminuria

20.5

21.8

20.8

Glycated hemoglobin
Percentage
Mean level — mmol/mol
BMI
Treatment assignment at start of clinical trial
—%

End of the clinical trial
Lack of maintenance of glycemic control — %‡
Complications — %

*	Plus–minus values are means ±SD. Shown are the characteristics of each cohort at entry into the TODAY trial (base‑
line) or at the end of the trial (February 2011). The second and third columns reflect the characteristics of the partici‑
pants from the TODAY trial who continued on to phase 1 and to phase 2 of the TODAY2 follow-up study. Data are excluded
for 22 participants in the TODAY trial cohort and 18 participants in the TODAY2 study cohorts who had confirmed
maturity-onset diabetes of the young. BMI denotes body-mass index.
†	Race and ethnic group were reported by the participants.
‡	Lack of maintenance of glycemic control was the primary outcome in the TODAY trial.

80.1% by 15 years (Fig. 2). In unadjusted models
and models adjusted for sex, race and ethnic
group, and age at randomization, the factors as
sociated with an increased risk of the develop
ment of any microvascular complication were
minority race or ethnic group, a high glycated
hemoglobin level, low insulin sensitivity, hyper
tension, and dyslipidemia (Table 2). There were
no differences according to the original treat
ment assignment. A sensitivity analysis that
420
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used the same unadjusted and adjusted models
yielded similar results (Table S5).
Clustering of Complications

At the time of the last visit, 270 of 677 partici
pants (39.9%) had no complications of diabetes,
215 (31.8%) had one complication, 144 (21.3%)
had two, and 48 (7.1%) had three (Fig. 2C). The
time to the onset of microvascular complications
is shown in Figure 2D, and the risk factors for
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A Mean and Median Glycated Hemoglobin Levels
100
10

Glycated Hemoglobin (%)

clustering of microvascular complications are
shown in Table 3. In univariable analyses, the
factors that were strongly associated with an
increased risk of accumulation of complications
were minority race or ethnic group, hyperglyce
mia, high BMI, low insulin sensitivity, hyperten
sion, and dyslipidemia. After adjustment for sex,
race and ethnic group, age, and diabetes dura
tion at randomization, BMI was no longer a risk
factor.

9

7

Median

6

Event Rates of Adjudicated Clinically
Identified Complications

Discussion
These prospective, longitudinal data indicate that
diabetes-related complications appear early in
youth-onset type 2 diabetes and accumulate rap
idly; at least one microvascular complication
developed in 60.1% of participants in the study.
In addition, a clustering of complications was
observed, with 28.4% of the participants having
two or more diabetes complications at a mean
age of 26.4 years; among these participants, the
mean time since the diagnosis of diabetes was
13.3 years. Furthermore, serious cardiovascular
events, although uncommon, occurred despite
the young age of the participants. Taken to
gether, these data illustrate the serious personal
and public health consequences of youth-onset
type 2 diabetes in the transition to adulthood.
The gravity of these data are underscored by
comparison with the risk of microvascular com
plications reported in type 1 diabetes and adult-

0

0

3

6

9

12

15

369

69

Follow-up (yr)
No. at Risk

677

513

453

451

B Distribution of Glycated Hemoglobin Levels
100
90

25

20
37

80

Participants (%)

The rate of all adjudicated heart, vascular, and
cerebrovascular events was 3.73 per 1000 per
son-years; there were 17 serious cardiovascular
events (myocardial infarction [4 events], conges
tive heart failure [6 events], coronary artery dis
ease [3 events], and stroke [4 events]). The rate
of all eye disease events, including 60 advanced
events, was 12.17 per 1000 person-years. The
rate of all liver, pancreas, or gallbladder events
was 6.70 per 1000 person-years. The rate of all
nerve events was 2.35 per 1000 person-years. For
all kidney events, including end-stage kidney
disease, the rate was 0.44 per 1000 person-years
(Table S6). Six deaths were reported (one each
from myocardial infarction, kidney failure, drug
overdose, and sepsis, and two from sepsis with
multiorgan failure).
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8
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0
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34

28
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6

9
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15

Follow-up (yr)

Figure 1. Glycated Hemoglobin Level over Time.
Shown are the mean and median glycated hemoglobin levels (Panel A) and
the distribution of glycated hemoglobin levels (Panel B) according to year.
Percentages may not total 100 because of rounding.

onset type 2 diabetes. Microvascular complica
tions, including diabetic kidney disease, affect
approximately 25% of young persons with a
duration of type 1 diabetes of more than 10
years.17 The Pittsburgh Epidemiology of Child
hood-Onset Diabetes Complications Study re
ported a cumulative risk of 32% for diabetic
kidney disease with a duration of type 1 diabetes
of 25 years.18 With respect to type 2 diabetes, the
U.K. Prospective Diabetes Study (UKPDS)
showed a prevalence of 25% for moderately in
creased albuminuria after 10 years, with an in
crease in incidence of 2% every year thereafter,
thus correlating with an estimated cumulative
risk of diabetic kidney disease of 55% at 25 years
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A Incidence of Complications

B Any Microvascular Disease
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0

6

Nerve Disease

Baseline prevalence, 20.8%
Cumulative incidence, 51.6%

0

Baseline prevalence, 9.0%
Cumulative incidence, 80.1%

75

Dyslipidemia
100

100

Baseline prevalence, 8.0%
Cumulative incidence, 54.8%

Incidence (%)

Baseline prevalence, 19.2%
Cumulative incidence, 67.5%

75
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Kidney Disease

Hypertension
100

of

50

25

0

3

6

9

12

0

15

3

0

Follow-up (yr)

6

9

12

15

Follow-up (yr)

C Number of Patients with Each Microvascular Complication

D Time to Onset of Microvascular Complications
Complication:

First

Second

Third

15

Nerve
39
103

45
80

48

67

25

Years to Onset of
Complications

Kidney

12
9
6
3
0

Retinal

1

2

3

No. of Microvascular Complications

Figure 2. Diabetes-Related Complications That Occurred during the Study.
Panel A shows the baseline prevalences and cumulative incidences of hypertension, dyslipidemia (low‑density‑lipoprotein or triglyceride
dyslipidemia), kidney disease, and nerve disease. Panel B shows the baseline prevalence and cumulative incidence of any microvascular
complication. The dashed lines in Panels A and B indicate the time when the cumulative incidence reached 50%, and the shaded bands
represent 95% confidence intervals. Baseline refers to the time of enrollment in the clinical trial. Panel C shows the numbers of patients
with kidney, nerve, and retinal complications. Panel D shows the years to onset of the first and subsequent (if applicable) microvascular
complications among participants with one, two, or three complications. The bottoms and tops of the boxes represent the first and the
third quartiles, respectively, and the horizontal lines inside the boxes indicate medians. The symbols inside the boxes indicate means,
and the symbols outside the boxes outliers. I bars indicate the minimum and maximum range, excluding outliers.

after the initial diagnosis.19 In the Diabetes Pre
vention Program (DPP) and DPP Outcome Study,
the incidence of the composite microvascular
outcome (kidney, nerve, and retinal diseases)
was between 12.3% and 14.4% among adult par
ticipants with type 2 diabetes.20
The reason for the high incidence of compli
cations in youthonset type 2 diabetes is un
known, but it is most likely related to the ex

422

n engl j med 385;5

treme metabolic phenotype (which includes
severe insulin resistance and rapid worsening of
betacell function2123) and to challenging socio
economic circumstances.24 In this cohort, the ac
cumulation of complications was tightly associ
ated with hyperglycemia, insulin resistance,
hypertension, and dyslipidemia. Unfortunately,
youthonset type 2 diabetes is characterized by a
suboptimal response to currently approved med
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Table 2. Unadjusted and Minimally Adjusted Models for the Risk of Any Microvascular Complication.*
Risk Factor

Hazard Ratio (95% CI)

Female vs. male

0.95 (0.78–1.16)

Race and ethnic group†
Hispanic vs. non-Hispanic White

1.50 (1.13–2.00)

Hispanic vs. non-Hispanic Black

1.02 (0.82–1.28)

Non-Hispanic Black vs. non-Hispanic White

1.46 (1.09–1.96)

Treatment assignment at start of clinical trial
Metformin plus rosiglitazone vs. metformin

1.23 (0.97–1.56)

Metformin plus lifestyle intervention vs. metformin

1.17 (0.92–1.48)

Metformin plus lifestyle intervention vs. metformin plus rosiglitazone

0.95 (0.75–1.21)

Age at baseline, per each increase of 1 yr of age

1.05 (1.00–1.10)

Duration of type 2 diabetes at baseline, per each increase of 1 mo
of duration

1.01 (0.99–1.02)

Unadjusted models
Glycated hemoglobin level, per each increase of 1% or 11 mmol/mol

1.18 (1.14–1.23)

BMI, per each increase of 5

1.08 (1.01–1.15)

Log insulin sensitivity, per each increase of 1 SD‡

0.81 (0.73–0.90)

Hypertension

1.39 (1.12–1.72)

Dyslipidemia

1.28 (1.03–1.59)

Adjusted models§
Glycated hemoglobin level, per each increase of 1% or 11 mmol/mol

1.18 (1.14–1.22)

BMI, per each increase of 5

1.07 (1.00–1.14)

Log insulin sensitivity, per each increase of 1 SD‡

0.80 (0.72–0.89)

Hypertension

1.44 (1.16–1.80)

Dyslipidemia

1.45 (1.16–1.82)

*	Any microvascular complication was defined as the first occurrence of kidney disease, nerve disease, or retinal disease.
Glycated hemoglobin, BMI, hypertension, and dyslipidemia were assessed at baseline and throughout follow-up. Insulin
sensitivity was assessed at baseline and through the end of phase 1 of the TODAY2 study, and the assessment was re‑
peated in phase 2 at 6 and 9 years after randomization where applicable. Each variable was analyzed as a time-varying
covariate in the model. CI denotes confidence interval.
†	The “other” category is excluded because of heterogeneity within the group.
‡	Insulin sensitivity was calculated as 1 ÷ fasting insulin.
§	The models were adjusted for the following preselected covariates: sex, race and ethnic group, and baseline age.

ical therapies,10,25,26 which is compounded by
major challenges in adherence and management
because of age and characteristic socioeconomic
factors.27 The only medications approved by the
Food and Drug Aministration (FDA) for youthonset type 2 diabetes are metformin and insulin,
with the recent addition of a glucagon-like pep
tide-1 (GLP-1) receptor agonist.28 Sodium–glucose
cotransporter 2 (SGLT2) inhibitors, which im
pede progression of cardiovascular and kidney
disease in patients with adult-onset type 2 dia
betes, are not yet approved by the FDA for youth-

n engl j med 385;5

onset type 2 diabetes, and whether SGLT2 in
hibitors and GLP-1 receptor agonists will have
cardioprotective and renoprotective effects in pa
tients with youth-onset type 2 diabetes is un
known. Metabolic bariatric surgery, an emerg
ing intervention for youth with type 2 diabetes,
results in durable weight loss and improvement
in glycemic control in the majority of pa
tients.29,30 Data from a collaboration between the
TODAY Study Group and the Teen–Longitudinal
Assessment of Bariatric Surgery (Teen-LABS)
showed a greater effect of bariatric surgery than
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Table 3. Unadjusted and Minimally Adjusted Models for the Risk of Accumulation of Microvascular Complications.*
Risk Factors

Number of Complications

Odds Ratio (95% CI)

0

1

2

3

34.8

31.2

34.7

54.2

0.84 (0.63–1.13)

Non-Hispanic Black

27.4

39.1

32.6

39.6

1.80 (1.20–2.68)

Hispanic

38.9

38.6

43.8

39.6

1.57 (1.06–2.33)

9.3

5.1

8.3

6.3

NA

24.4

17.2

15.3

14.6

—

Metformin plus rosiglitazone

35.9

32.6

31.3

31.3

0.97 (0.69–1.36)

Metformin plus lifestyle intervention

33.0

37.2

29.9

25.0

1.31 (0.93–1.84)

Metformin

31.1

30.2

38.9

43.8

—

14.0±2.0

14.0±2.0

13.8±2.1

14.7±1.9

1.02 (0.95–1.09)

7.4±5.6

7.8±5.8

8.4±6.4

7.8±5.4

1.02 (0.99–1.04)

7.0±1.7

8.2±1.9

9.6±1.7

10.4±1.3

1.78 (1.64–1.93)

35.5±6.9

36.9±8.3

35.6±7.4

39.4±8.9

1.09 (1.00–1.20)

0.054±0.030

0.046±0.026

0.043±0.026

0.038±0.017

0.65 (0.56–0.74)

Female vs. male — %
Race and ethnic group, vs. Non-Hispanic White
— %†

Other
Non-Hispanic White
Treatment, vs. metformin — %‡

Age at baseline, per each increase of 1 yr of age
Duration of type 2 diabetes at baseline, per
each increase of 1 mo of duration
Unadjusted models
Glycated hemoglobin level, per each increase
of 1% or 11 mmol/mol
Mean BMI, per each increase of 5
Mean log insulin sensitivity, per each increase
of 1 SD§
Hypertension — %

40.7

61.9

72.2

83.3

3.09 (2.31–4.15)

Dyslipidemia — %

40.4

54.0

70.8

66.7

2.43 (1.83–3.22)

Adjusted models¶
Glycated hemoglobin level, per each increase
of 1% or 11 mmol/mol

1.80 (1.65–1.95)

BMI, per each increase of 5

1.09 (0.99–1.19)

Natural log insulin sensitivity, per each
increase of 1 SD§

0.64 (0.56–0.74)

Hypertension

3.18 (2.35–4.30)

Dyslipidemia

2.77 (2.05–3.72)

*	Plus–minus values are means ±SD. NA denotes not applicable.
†	The odds ratio for the “other” category was not calculated because of heterogeneity within the group. The odds ratio for non-Hispanic Black
versus Hispanic was −0.13 (95% CI, −0.45 to 0.19).
‡	The odds ratio for metformin plus lifestyle intervention versus metformin plus rosiglitazone was 0.74 (95% CI, 0.53 to 1.04).
§	Insulin sensitivity was defined as 1 ÷ fasting insulin.
¶	The models were adjusted for the following preselected covariates: sex, race and ethnic group, baseline age, and baseline duration of type 2
diabetes.

medical therapy on both glycemic and nonglyce
mic outcomes.29 Teen-LABS showed greater re
gression and earlier attenuation of kidney dis
ease in youth with type 2 diabetes than in adults
with type 2 diabetes.31,32
Given the associations of hyperglycemia, hyper
tension, and dyslipidemia with a high risk for
424
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the development of complications, studies explor
ing early aggressive management of glycemia
and risk factors in youth-onset type 2 diabetes
are needed. However, until such data are avail
able, primary and secondary prevention strate
gies based on extrapolation of data from studies
in adults, including the use of medications not
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yet approved for youths, need to be considered.
In addition, understanding of health care needs
and health care usage patterns of young adults
with youth-onset type 2 diabetes is needed so
that health care systems in countries with large
populations of persons with youth-onset type 2
diabetes are prepared for the anticipated needs.
Strengths of this study include a large sample
of participants with youth-onset type 2 diabetes
with up to 15 years of prospective, comprehen
sive, and rigorous phenotyping. The diverse co
hort is representative of the general population
with youth-onset type 2 diabetes in the United
States.2,27 In addition, the assessment of compli
cations was predefined and adjudicated. How
ever, the incomplete follow-up of a quarter of the
original cohort may have resulted in underrepre
sentation of the accumulation and clustering of
events, although the findings were consistent in
the sensitivity analyses. Also, nicotine use is
recognized as an important cardiovascular risk
factor; information on participants’ history of
nicotine use was collected but was identified as
unreliable during analysis. The participants were
willing to take part in an intensive clinical trial
and received intensive management at no cost as
part of the study until 2014; therefore, the inci
dence of complications might have been even
higher in the absence of these interventions. Fi
nally, the lack of longitudinal data on microvas
cular complications in adolescents without dia
betes but with a similar degree of obesity
precludes comparison of event rates among
youth with and without type 2 diabetes. Of note,

the most diabetes-specific complications, such
as eye disease, are widely recognized not to oc
cur in populations without diabetes.33
These data show a high burden of diabetesspecific complications in youth-onset type 2 dia
betes, with an early and severe effect on persons
with this disease, as well as substantial public
health implications.
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